Similarly, ImmunoGenes’ FcRn transgenic rabbits have shown an identical robust antibody-mediated immune response against a variety of difficult antigens to that observed in transgenic mice (Figure 1), making them ideally suited for the production of high-quality polyclonal antibody in shorter time periods if desired. Furthermore, immunized FcRn transgenic rabbits can also be used for the development of rabbit monoclonal antibodies, an increasingly sought-after commodity in the biopharmaceutical industry.
FcRn transgenic rabbits are ideally suited for the development and production of anti-host cell protein lysate (HCP) polyclonal antibodies capable of recognizing weakly and highly immunogenic components of the HCP mixture—generally classified as a mixture of difficult antigens, with greater than 90% coverage. In turn, the developed reagent is ideal for equivalent detection of low and high molecular proteins and can be incorporated into clearance studies of new drugs developed and manufactured by the pharmaceutical industry in a variety of different expression systems.
FcRn has been identified in mediating maternal IgG transport, regulating IgG metabolism, significantly preventing IgG catabolism in a concentration-dependent manner, and playing a crucial role in the antigen-IgG immune complex presentation. Overexpression of this receptor in transgenic animals therefore aids in the increased rescue of antigen-specific IgG molecules and improves antigen presentation resulting in greatly augmented antibody-mediated immune responses against antigens that cannot be compared to that potentially induced in wild-type or knock-out animals over the course of an immunization regimen.
The implications of such are that, presently, this alternative technology is accessible to the greater biopharmaceutical and research community for the development of monoclonal or polyclonal antibodies against weakly immunogenic and/or highly homologous antigens when traditional antibody development approaches have not succeeded, making it extremely appealing for the development of diagnostic and therapeutic antibodies incorporated into tomorrow’s disease-specific assays and treatment programs.